WordNet
- be a contributing factor; "make things factor into a companys profitability"
- any of the numbers (or symbols) that form a product when multiplied together
- an independent variable in statistics
- anything that contributes causally to a result; "a number of factors determined the outcome"
- consider as relevant when making a decision; "You must factor in the recent developments" (同)factor in, factor out
- resolve into factors; "a quantum computer can factor the number 15" (同)factor in, factor out
- smear with blood, as in a hunting initiation rite, where the face of a person is smeared with the blood of the kill
- temperament or disposition; "a person of hot blood"
- people viewed as members of a group; "we need more young blood in this organization"
- the fluid (red in vertebrates) that is pumped through the body by the heart and contains plasma, blood cells, and platelets; "blood carries oxygen and nutrients to the tissues and carries away waste products"; "the ancients believed that blood was the sea
- an event known to have happened or something known to have existed; "your fears have no basis in fact"; "how much of the story is fact and how much fiction is hard to tell"
- a concept whose truth can be proved; "scientific hypotheses are not facts"
- a piece of information about circumstances that exist or events that have occurred; "first you must collect all the facts of the case"
- a statement or assertion of verified information about something that is the case or has happened; "he supported his argument with an impressive array of facts"
- the 22nd letter of the Roman alphabet (同)v
PrepTutorEJDIC
- (…の)『要因』,(…を生み出す)要素《+『in』+『名』(do『ing』)》 / 囲数,約数 / 代理人,《おもに英》仲買人 / =factorize
- 『血』,『血』液 / 流血(bloodshed);殺人 / 気質,気性,血気,血潮 / 『血統』,血縁(kinship);生まれ,家柄;《the~》王家の血統 / (人種・出身国の)系 / 〈人〉‘に'初めての経験をさせる / 〈猟犬〉‘に'初めて獲物を血を味わわせる
- 〈C〉『事実』,実際にある(あった)事 / 〈U〉真相,真実(truth) / 《the~》(法律用語で)犯行
- vanadium の化学記号
- 純血の,純種の / 《複合語を作って》「…の血(性質)を持った」の意を表す
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 重症患者における血液製剤の使用 use of blood products in the critically ill
- 2. 血漿分画製剤および組換えDNA産生凝固因子 plasma derivatives and recombinant dna produced coagulation factors
- 3. 静脈血栓症の原因の概要 overview of the causes of venous thrombosis
- 4. 胎児の採血 fetal blood sampling
- 5. 止血の概要 overview of hemostasis
English Journal
- EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma.
- Zhang B1, Wang H1, Liao Z2, Wang Y2, Hu Y3, Yang J3, Shen S2, Chen J2, Mei H1, Shi W1, Hu Y4, Pang Z5, Jiang X2.Author information 1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei 430022, PR China.2School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, 826 Zhangheng Road, Shanghai 201203, PR China.3College of Pharmacy, Jiamusi University, Jiamusi 154007, PR China.4Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei 430022, PR China. Electronic address: dr_huyu@126.com.5School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, 826 Zhangheng Road, Shanghai 201203, PR China. Electronic address: zqpang@fudan.edu.cn.AbstractAs neovascular and glioma cells were closely associated and might be mutually promoted in glioma growth, a dual-targeting strategy targeting to both neovascular and glioma cells would be more promising as compared with those targeting one of them. In this study, we reported a drug delivery system where nanoparticles were decorated with EGFP-EGF1 (ENP), a fusion protein derived from factor VII with special affinity for tissue factor (TF) over-expressed in glioma tissues, to facilitate anti-glioma delivery of paclitaxel (PTX) by targeting both neovascular and glioma cells. In vitro protein binding assay demonstrated that EGFP-EGF1 bound well to C6 cells and perturbed human umbilical vein endothelial cells (HUVEC) with a concentration-dependent manner but not to unperturbed HUVEC. EGFP-EGF1-TF interaction significantly enhanced nanoparticles uptake by perturbed HUVEC and glioma C6 cells as well as nanoparticles penetration in C6 glioma spheroids, and thus improved the cytotoxicity of their payload in both monolayer cells and glioma spheroids models. In vivo imaging of glioma-bearing mice demonstrated the specific accumulation of ENP in glioma tissues. In vivo distribution of nanoparticles intuitively showed ENP mainly sited in both extravascular glioma cells and neovascular cells. Pharmacodynamic results revealed that PTX-loaded ENP (ENP-PTX) significantly prolonged the median survival time of glioma-bearing mice compared with that of any other group. TUNEL assay and H&E staining showed that ENP-PTX treatment induced significantly more cell apoptosis and tumor necrosis compared with other treatments. In conclusion, the results of this contribution demonstrated the great potential of EGFP-EGF1-functionalized nanoparticles for dual-targeting therapy of brain glioma.
- Biomaterials.Biomaterials.2014 Apr;35(13):4133-45. doi: 10.1016/j.biomaterials.2014.01.071. Epub 2014 Feb 14.
- As neovascular and glioma cells were closely associated and might be mutually promoted in glioma growth, a dual-targeting strategy targeting to both neovascular and glioma cells would be more promising as compared with those targeting one of them. In this study, we reported a drug delivery system wh
- PMID 24529623
- Compositional differences in commercially available prothrombin complex concentrates.
- Sadeghi N1, Kahn D, Sayed D, Hoppenstadt D, Jeske W, Harenberg J, Dechristopher P, Fareed J.Author information 11Department of Pathology, Loyola University Medical Center, Maywood, IL, USA.AbstractProthrombin complex concentrates (PCCs) are used in the management of bleeding complications with conventional oral anticoagulant drugs. Since the activation of these complexes results in the generation of factor Xa and IIa, these agents may potentially neutralize the newly developed Xa and thrombin inhibitors. Although the potency of these agents is defined in units that represent the level of factor IX (FIX), other factors including factor II, VII, and X are also present. Protein C, protein S, and protein Z are also present. The purpose of this study is to compare the compositional differences in the currently available PCCs along with the older agents. Measurement of compositional parameters including protein and FIX, mass spectrometric analysis of the native and activated PCCs, Western blotting studies on the native and activated PCCs for the activation products including thrombin, and their effect on blood and plasma coagulation parameters were carried out.
- Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.Clin Appl Thromb Hemost.2014 Apr;20(3):256-69. doi: 10.1177/1076029613511523. Epub 2013 Nov 27.
- Prothrombin complex concentrates (PCCs) are used in the management of bleeding complications with conventional oral anticoagulant drugs. Since the activation of these complexes results in the generation of factor Xa and IIa, these agents may potentially neutralize the newly developed Xa and thrombin
- PMID 24288386
- Antimicrobial responses of teleost phagocytes and innate immune evasion strategies of intracellular bacteria.
- Grayfer L1, Hodgkinson JW2, Belosevic M3.Author information 1Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA.2Department of Biological Sciences, University of Alberta, Edmonton, Canada.3Department of Biological Sciences, University of Alberta, Edmonton, Canada; School of Public Health, University of Alberta, Edmonton, Canada. Electronic address: mike.belosevic@ualberta.ca.AbstractDuring infection, macrophage lineage cells eliminate infiltrating pathogens through a battery of antimicrobial responses, where the efficacy of these innate immune responses is pivotal to immunological outcomes. Not surprisingly, many intracellular pathogens have evolved mechanisms to overcome macrophage defenses, using these immune cells as residences and dissemination strategies. With pathogenic infections causing increasing detriments to both aquacultural and wild fish populations, it is imperative to garner greater understanding of fish phagocyte antimicrobial responses and the mechanisms by which aquatic pathogens are able to overcome these teleost macrophage barriers. Insights into the regulation of macrophage immunity of bony fish species will lend to the development of more effective aquacultural prophylaxis as well as broadening our understanding of the evolution of these immune processes. Accordingly, this review focuses on recent advances in the understanding of teleost macrophage antimicrobial responses and the strategies by which intracellular fish pathogens are able to avoid being killed by phagocytes, with a focus on Mycobacterium marinum.
- Developmental and comparative immunology.Dev Comp Immunol.2014 Apr;43(2):223-42. doi: 10.1016/j.dci.2013.08.003. Epub 2013 Aug 15.
- During infection, macrophage lineage cells eliminate infiltrating pathogens through a battery of antimicrobial responses, where the efficacy of these innate immune responses is pivotal to immunological outcomes. Not surprisingly, many intracellular pathogens have evolved mechanisms to overcome macro
- PMID 23954721
Japanese Journal
- A case of acquired hemophilia A with massive hemothorax
- FUKUSHIMA Tomihiro,MIKANE Takeshi,ONO Daisuke,OKU Satoru,KOBAYASHI Hiroyuki,WATANABE Yoko,IWASAKI Etsu,ISHII Mizue,TOKIOKA Hiroaki
- Journal of anesthesia 26(2), 262-264, 2012-04-20
- NAID 10030759177
- Effects of pregnancy and lactation on warfarin-induced changes in blood coagulation-related parameters in rats
- Ohishi Takumi,Kitazawa Takahiro,Suzuki Saori [他],NAKAMURA Daichi,NISHIHARA Yoshito,MOCHIZUKI Masahiro
- Journal of toxicological sciences 35(2), 189-196, 2010-04-01
- … Effects of pregnancy and lactation on warfarin-induced changes in blood coagulation-related parameters were examined in rats. … Blood samples were collected from the rats on the day following the last administration (GD 20 or PPD 13) to measure prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), thrombotest (TBT), factor VII and X activities and anti-thrombin III concentration (ATIII). …
- NAID 10026193274
- Changes in blood coagulation-related parameters in phenobarbital-treated rabbits
- Mochizuki Masahiro,Abe Hajime,Wakabayashi Kei [他],Yoshinaga Hiroyasu,Okazaki Emi,Saito Tsubasa,Fujita Mariko,Edamoto Hiroshi,Asano Yuzo
- Journal of toxicological sciences 34(4), 357-362, 2009-08-01
- … The effects of repeated administration of phenobarbital (PB) on blood coagulation time were examined using male Japanese white SPF rabbits, which are widely used for toxicological studies. … Blood was collected on Days 8 and 14 after each day's dosing to perform blood coagulation examination. …
- NAID 110007359664
Related Links
- Blood Coagulation Factor VII (n.) 1. (MeSH) Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the ...
- Background Blood coagulation is a complex reaction network that functions to form a fibrin clot that covers damaged vessel wall and prevents blood loss [1]. The clotting process is initiated by tissue factor (TF), a ...
Related Pictures
★リンクテーブル★
| リンク元 | 「stable factor」「血液凝固第VII因子」「coagulation factor VII」 |
| 拡張検索 | 「blood coagulation factor VIII」 |
| 関連記事 | 「fact」「factor」「V」「coagulation factor」「blood」 |
「stable factor」
- 関
- blood coagulation factor VII、coagulation factor VII、factor VII、coagulation factors, factor VII
「血液凝固第VII因子」
「coagulation factor VII」
「blood coagulation factor VIII」
「fact」
- n.
「factor」
- n.
「V」
「coagulation factor」
「blood」